Research progress in immune checkpoint inhibitor-related thrombotic events
10.3760/cma.j.cn114015-20220615-00532
- VernacularTitle:免疫检查点抑制剂相关血栓事件的研究进展
- Author:
Xuan YE
1
;
Yufang YOU
1
;
Feifei GAO
1
;
Xuan XU
1
;
Qing ZHAI
1
Author Information
1. 复旦大学附属肿瘤医院药剂科，上海 200032
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Thrombosis;
Drug-related side effects and adverse reactions;
Review
- From:
Adverse Drug Reactions Journal
2023;25(3):172-177
- CountryChina
- Language:Chinese
-
Abstract:
With the widespread clinical use of immune checkpoint inhibitors (ICIs), the risk of thrombotic events has also increased, which is related to the poor survival rate. Most studies indicate that ICIs treatment may increase the risk of thrombotic events in tumor patients, but the correlation is still controversial. The incidence and risk factors of thrombotic events are various in different studies. Patients with malignant tumors of lung, skin, and genitourinary system are at high risk of thrombotic events. The clinical types of thrombotic events are mainly pulmonary embolism, myocardial infarction, and deep vein thrombosis. The mortality rate in patients with thrombotic events is high. At present, there are no guidelines or consensus on the management of thrombosis risk related to ICIs. To improve the understanding of these adverse effects in clinic, this article reviews the correlation between ICIs and thrombotic events, and the incidence, risk factors, pathogenesis, prevention, and treatment of relevant thrombotic events.
